Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

被引：46

作者：

Rha, S. Y. ^{[1
]}

Wyrwicz, L. S. ^{[2
]}

Weber, P. E. Y. ^{[3
]}

Bai, Y. ^{[4
]}

Ryu, M. H. ^{[5
]}

Lee, J. ^{[6
]}

Rivera, F. ^{[7
]}

Alves, G. V. ^{[8
]}

Garrido, M. ^{[9
]}

Shiu, K. -k. ^{[10
]}

Fernandez, M. Gonzalez ^{[11
]}

Li, J. ^{[12
]}

Lowery, M. ^{[13
]}

Cil, T. ^{[14
]}

Cruz, F. J. S. M. ^{[15
]}

Qin, S. ^{[16
]}

Yin, L. ^{[17
]}

Bordia, S. ^{[18
]}

Bhagia, P. ^{[18
]}

Oh, D-y. ^{[19
]}

机构：

[1] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Internal Med, Seoul, South Korea

[2] Mar Sklodowska Curie Natl Res Inst Oncol, Oncol & Radiotherapy, Warsaw, Poland

[3] Univ La Frontera, James Lind Canc Res Ctr, Internal Med, Temuco, Chile

[4] Harbin Med Univ, Canc Hosp, Gastrointestinal Oncol, Harbin, Peoples R China

[5] Univ Ulsan, Asan Med Ctr, Oncol, Coll Med, Seoul, South Korea

[6] Sungkyunkwan Univ, Samsung Med Ctr SMC, Hematol & Oncol, Sch Med, Seoul, South Korea

[7] Hosp Univ Marques de Valdecilla, Med Oncol, Santander, Spain

[8] Hosp Nossa Senhora Conceicao, Med Oncol, Porto Alegre, Brazil

[9] Univ Mayor, Oncol, Santiago, Chile

[10] Univ Coll Hosp NHS Fdn Trust, Oncol, London, England

[11] IMAT Oncomed, Monteria, Colombia

[12] Tongji Univ, Shanghai East Hosp, Med Oncol, Sch Med, Shanghai, Peoples R China

[13] Trinity St James Canc Inst, Med Oncol, Dublin, Ireland

[14] Hlth & Sci Univ, Adana City Hosp, Med Oncol, Adana, Turkiye

[15] Nucleo Pesquisa & Ensino Rede Sao Camilo, Med Oncol, Sao Paulo, Brazil

[16] Canc Ctr Peoples Liberat Army, Med Oncol, Nanjing, Peoples R China

[17] Merck & Co Inc, Biostat & Res Decis Sci, Rahway, NJ USA

[18] Merck & Co Inc, Global Clin Dev, Rahway, NJ USA

[19] Seoul Natl Univ, Internal Med, Coll Med, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷 / 03期

关键词：

D O I：

10.1016/j.annonc.2023.01.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：319 / 320

页数：2

共 50 条

[21] KEYNOTE-062:Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Tabernero, Josep
Bang, Yung-Jue
Fuchs, Charles S.
Ohtsu, Atsushi
Kher, Uma
Lam, Baohoang
Koshiji, Minori
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[22] Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
Tabernero, Josep
Van Cutsem, Eric
Bang, Yung-Jue
Fuchs, Charles S.
Wyrwicz, Lucjan
Lee, Keun Wook
Kudaba, Iveta
Garrido, Marcelo
Chung, Hyun Cheol
Salguero, Hugo Raul Castro
Mansoor, Wasat
Braghiroli, Maria Ignez Freitas Melro
Goekkurt, Eray
Chao, Joseph
Wainberg, Zev A.
Kher, Uma
Shah, Sukrut
Kang, SoonMo Peter
Shitara, Kohei
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
[23] KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Tabernero, Josep
Bang, Yung-Jue
Fuchs, Charles S.
Ohtsu, Atsushi
Kher, Uma
Lam, Baohoang
Koshiji, Minori
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[24] Neoadjuvant/adjuvant pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585
Shitara, Kohei
Bang, Yung-Jue
Wyrwicz, Lucjan S.
Rha, Sun Young
Oshima, Takashi
Di Bartolomeo, Maria
Park, Young-Kyu
Lonardi, Sara
Weber, Patricio Eduardo Yanez
Yen, Chia-Jui
Metges, Jean-Philippe
Garrido, Marcelo
Moehler, Markus H.
Pelles-Avraham, Sharon
Yong, Wei-Peng
Spallanzani, Andrea
Jensen, Erin
Krishnan, Radha
Shih, Chie-Schin
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[25] First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Shen, Lin
Zhang, Yanqiao
Li, Ziyu
Zhang, Xiaotian
Gao, Xiangyu
Liu, Bo
Wang, Yusheng
Ba, Yi
Li, Ning
Zhang, Ruixing
Zhang, Jingdong
Chen, Ye
Chen, Jian
Huang, Mingzhu
Fu, Yang
Liu, Mulin
Liu, Zheng
Zhao, Jun
Li, Wei
Wei, Jia
Li, Changzheng
Xu, Nong
Guo, Zengqing
Cao, Bangwei
Liu, Lian
Nie, Peng
Wan, Lixin
Sheng, Lili
Liu, Zhenyang
He, Yifu
Gu, Kangsheng
Wu, Guowu
Wang, Weibo
Zhang, Futong
Qiu, Wensheng
Guo, Jun
Ying, Jieer
Pan, Hongming
Xu, Huiting
Yuan, Yuan
Bai, Yuansong
Wang, Zhenghua
Xu, Jiye
Zhao, Xuehong
Liu, Hao
Zhang, Xizhi
Dai, Wenxiang
Xu, Hongyan
Liu, Ming
Xie, Lin
NATURE MEDICINE, 2025, : 1163 - 1170
[26] Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study
Xu, J.
Jiang, H.
Pan, Y.
Gu, K.
Cang, S.
Han, L.
Shu, Y.
Li, J.
Zhao, J.
Pan, H.
Luo, S.
Qin, Y.
Guo, Q.
Bai, Y.
Ling, Y.
Guo, Y.
Li, Z.
Liu, Y.
Wang, Y.
Zhou, H.
ANNALS OF ONCOLOGY, 2021, 32 : S1331 - S1331
[27] Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).
Alva, Ajjai Shivaram
Csoszi, Tibor
Ozguroglu, Mustafa
Matsubara, Nobuaki
Geczi, Lajos
Cheng, Susanna Y.
Fradet, Yves
Oudard, Stephane
Vulsteke, Christof
Morales-Barrera, Rafael
Flechon, Aude
Gunduz, Seyda
Loriot, Yohann
Rodriguez-Vida, Alejo
Mamtani, Ronac
Yu, Evan Y.
Nam, Kijoeng
Imai, Kentaro
Moreno, Blanca Homet
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[28] Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy
Chao, Joseph
Fuchs, Charles S.
Shitara, Kohei
Tabernero, Josep
Muro, Kei
Van Cutsem, Eric
Bang, Yung-Jue
De Vita, Ferdinando
Landers, Greg A.
Yen, Chia-Jui
Chau, Ian
Elme, Anneli
Lee, Jeeyun
Ozguroglu, Mustafa
Catenacci, Daniel V. T.
Li, Xiaodong
Shih, Chie-Schin
Shah, Sukrut
Bhagia, Pooja
Wainberg, Zev A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[29] Phase III study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)
Peng, Z.
Wang, J.
Zhang, Y.
Li, H.
Zhao, Q.
Zhu, X.
Wei, S.
Cheng, Y.
Yang, W.
Yao, J.
Zhang, M.
Xie, L.
Zhang, X.
Zhao, P.
Hu, C.
Zhang, J.
Wang, Z.
Wang, W.
Han, H.
Shen, L.
ANNALS OF ONCOLOGY, 2024, 35 : 1250 - 1250
[30] Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.
Janjigian, Yelena Y.
Kawazoe, Akihito
Yanez, Patricio Eduardo
Luo, Suxia
Lonardi, Sara
Kolesnik, Oleksii
Barajas, Olga
Bai, Yuxian
Shen, Lin
Tang, Yong
Wyrwicz, Lucjan
Shitara, Kohei
Qin, Shukui
Van Cutsem, Eric
Tabernero, Josep
Li, Lie
Shih, Chie-Schin
Bhagia, Pooja
Chung, Hyun Cheol Cheol
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →